araag2/HINT huggingface dataset:
Clinical trial NCT00558844 (phase 1/phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: arikayce™ 560 mg, placebo for 560 mg, arikayce™ 70 mg, arikayce™ 140 mg, placebo for 70 mg / 140 mg
SMILES: NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female study subjects must be adults (≥ 6 years of age)

          -  Confirmed diagnosis of CF

          -  History of chronic infection with P.aeruginosa

          -  FEV1 ≥40% of predicted at Screening

          -  Ability to comply with study medication use, study visits and procedures

          -  Ability to produce 0.5 grams of sputum

        Key Exclusion Criteria:

          -  Administration of any investigational drug within 8 weeks to Study Day 1

          -  Emergency room visit or hospitalization for CF or respiratory-related illness within 4
             weeks prior to screening

          -  History of alcohol, medication or illicit drug abuse within 1 yr. to screening

          -  History of lung transplantation

          -  Female of childbearing potential who are not practicing an acceptable method of birth
             control or who are lactating

          -  Positive Pregnancy test

          -  Use of any anti-pseudomonal antibiotics within 28 days prior to Study Day 1

          -  Initiation of chronic therapy within 28 days prior to Study Day 1

          -  History of sputum or throat swab culture yielding Burkholderia cepacia within 2 years
             prior to screening

          -  History of mycobacterial and/or Aspergillus infection requiring treatment within 2
             years prior to screening

          -  History of biliary cirrhosis with portal hypertension, or splenomegaly
Clinical trial NCT00590460 (phase 1/phase 2, status: terminated)
Conditions: fanconi anemia, severe aplastic anemia
ICD codes: D61.3, D61.9, D61.09, D61.1, D61.2, D61.89
Drugs: fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

        Diagnosis of Fanconi Anemia or other suspected DNA breakage/chromosomal instability
        syndromes, such as dyskeratosis congenita or Nijmegen breakage syndrome of all ages are
        eligible.

        Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow
        sensitivity to mitomycin C or DEB or clinical evidence of other DNA breakage/chromosomal
        instability syndrome as determined by genetic testing or clinical diagnosis by a geneticist

        Severe aplasia anemia as evidenced by a hypocellular bone marrow and at least 1 of the 3
        criteria below: ANC < 500/mm3 Hemoglobin < 10 gm/dl with reticulocyte count < 1% Platelet
        count < 50,000/mm3

        Availability of an HLA matched or mismatched (up to one haplotype) family member who has
        been documented not to have Fanconi anemia or of an unrelated HLA matched stem cell donor.
        Fully matched is defined at 6/6 match by high resolution DR based DNA typing.

        Life expectancy greater than 6 weeks limited by diseases other than FA

        Creatinine 2X normal for age or less

        Karnofsky score 70% or more

        Exclusion Criteria:

        Patients with symptomatic cardiac disease, or evidence of significant cardiac disease by
        echocardiogram (i.e., shortening fraction less than 25%).

        Patients with known allergy to rat serum products.

        Patients with a severe infection that on evaluation by the Principal Investigator precludes
        ablative chemotherapy or successful transplantation.

        Patients with severe personality disorder or mental illness.

        Patients with documented HIV positivity.

        Pregnant

        NOTE: Patients who would be excluded from the protocol strictly for laboratory
        abnormalities can be included at the investigator's discretion after approval by the CCGT
        Protocol Review Committee and the FDA Reviewer.
Clinical trial NCT01050985 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: temsirolimus and capecitabine
SMILES: CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven adenocarcinoma with measurable or evaluable disease

          -  Disease for which capecitabine is approved or compendia listed

          -  Advanced unresectable, and/or metastatic disease for which there is no known curative
             therapy

          -  Performance status 0-2

          -  Adequate hepatic, bone marrow, and renal function

        Exclusion Criteria:

          -  Brain metastases not under control for at least 3 months

          -  Active severe infection or known chronic infection with HIV, hepatitis B virus, or
             hepatitis C virus

          -  Cardiovascular disease problems including unstable angina, therapy for
             life-threatening ventricular arrhythmia, or myocardial infarction, stroke, or
             congestive heart failure within the last 6 months

          -  Life-threatening visceral disease or other severe concurrent disease

          -  Women who are pregnant or breastfeeding

          -  Anticipated patient survival under 3 months
Clinical trial NCT01825785 (phase 1, status: completed)
Conditions: postmenopausal, osteopenia
ICD codes: N95.0, N95.2
Drugs: romosozumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy males and females between 45 to 80 years of age

          -  Postmenopausal females

          -  Low bone mineral density, defined by bone mineral density (BMD) T-scores between -1.0
             and -2.5, inclusive, for the lumbar spine [L1-L4] or total evaluable vertebrae [if
             fewer than L1-L4] or total hip)

          -  25-hydroxyvitamin D ≥ 20 ng/mL

          -  Weight ≤ 98 kg (216 lb) and/or height ≤ 196 cm (77 in)

        Exclusion Criteria:

          -  Osteoporosis defined by bone mineral density (BMD) T-scores < -2.5 for the lumbar
             spine (L1-L4) or total evaluable vertebrae (if fewer than L1-L4) or total hip

          -  Diagnosed with any condition that would affect bone metabolism

          -  Previous exposure to AMG 785
Clinical trial NCT01060514 (phase 1, status: terminated)
Conditions: metastatic non small cell lung cancer, metastatic breast cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pazopanib, vinorelbine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    lack of timely accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years

          -  Patients must have diagnosis of breast cancer or non small cell lung cancer

          -  Patients must have evaluable disease

          -  Women of childbearing potential and sexually active males must commit to the use of
             effective contraception while on study.

          -  Patients must have given signed, informed consent prior to registration on study.

        Exclusion Criteria:

          -  Patients must not be pregnant and/or lactating.

          -  Patients must not be receiving any other investigational agents.

          -  No prior exposure to vinorelbine or other VEGF inhibitors as treatment for metastatic
             disease

          -  Patients must not have received prior therapy (including radiation, surgery, and/or
             chemotherapy) within 30 days

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to pazopanib or vinorelbine.

          -  Patients cannot have received more than 2 prior chemotherapy regimens for lung cancer
             or 3 prior chemotherapy regimens for breast cancer. This criterion can be discussed
             further with the study doctor.

          -  Must not have uncontrolled illness including, but not limited to: ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmic, psychiatric illness/social situations that would limit compliance with
             study requirements.
Clinical trial NCT00702923 (phase 1, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: bicalutamide and cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206 (tremelimumab), bicalutamide, cp-675,206
SMILES: CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F, CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F, CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F, CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F, CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F
Reason stopped: 
    enrollment was halted prematurely due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age & histologic diagnosis of adenocarcinoma of the prostate

          -  Completed surgery or radiation at least 8 weeks prior to entry with removal of all
             visible disease

          -  Clinical Stage D0 prostate cancer with rising PSA and PSA >2ng/ml.

          -  ECOG performance of <2

          -  Normal hematologic, renal and liver function

        Exclusion Criteria:

          -  Cannot have evidence of immunosuppression or have been treated with immunosuppressive
             therapy.

          -  No prior treatment with an LHRH agonist or nonsteroidal antiandrogen such as casodex
             or flutamide

          -  No evidence for metastatic disease per bone scan or CT scan of the abdomen and pelvis

          -  No prior treatment with anti-CTLA 4 monoclonal antibody

          -  No history of known autoimmune disorder or HIV, hepatitis B or hepatitis C

          -  No known brain metastases

          -  No history of inflammatory bowel conditions including diverticulitis, ulcerative
             colitis, etc.
Clinical trial NCT00560820 (phase 1, status: completed)
Conditions: β-thalassemia, transfusional iron overload
ICD codes: E87.70, E87.79, E87.71
Drugs: deferasirox
SMILES: CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN
Eligibility criteria:

        Inclusion criteria:

          -  Male or female patients ≥ 18 years of age without prior history of deferasirox
             treatment

          -  β-thalassemia patients receiving regular transfusions every 2-5 weeks

          -  Transfusion history of ≥ 20 units of packed red blood cells

        Exclusion criteria:

          -  Abnormal renal function at baseline

          -  ALT greater than 5 x ULN at screening

          -  Patients with underlying cardiac disease requiring continuous iron chelation therapy

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00546715 (phase 1/phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: daclatasvir, placebo
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Chronically infected with hepatitis C virus genotype 1

          -  Treatment naive or treatment non-responders or treatment intolerant; and not
             co-infected with HIV or hepatitis B virus

          -  Hepatitis C virus RNA viral load of ≥ 10*5* IU/mL

          -  BMI 18 to 35 kg/m²

        Key Exclusion Criteria:

          -  Any significant acute or chronic medical illness which is not stable or is not
             controlled with medication and not consistent with hepatitis C virus infection

          -  Major surgery within 4 weeks of study drug administration and any gastrointestinal
             surgery that could impact the absorption of study drug
Clinical trial NCT00287170 (phase 1/phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: delayed release 6mp or calcitriol vs. purinethol
SMILES: C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female patients, aged 18-75 years with moderate Crohn's Disease (CDAI score
             >=220 and <=400 at screening), with or without adjunctive mesalamine treatment, 12
             with involvement of the ileum and three without ileal involvement

          -  Definitive diagnosis of active inflammatory CD with fibrostenosing and/or
             fistulizing/perforating CD types ruled out based on clinical and radiological or
             endoscopic or pathological findings, within the previous 6 months

        Exclusion Criteria:

          -  Body weight below 42.5 kg

          -  Subjects who have received either methotrexate, cyclosporine or anti-TNFalpha
             (infliximab, Remicade), anti-integrin (namixilab) in the past 3 months

          -  Subjects who are taking allopurinol, sulfasalazine, valerian, warfarin and
             corticosteroids,including budesonide and prednisone within 28 days prior to and
             throughout the study

          -  Previous bowel resection, including prior colostomy, ileostomy or colectomy with
             ileorectal anastomosis

          -  Symptomatic stenosis or ileal strictures; x-ray evidence of fibrosed bowel

          -  Subjects with ulcerative colitis or short bowel syndrome

          -  Subjects who present with, or with a history of persistent intestinal obstruction,
             bowel perforation, uncontrolled GI bleed or abdominal abscess or infection, toxic
             megacolon

          -  Subjects with fistulizing CD or isolated small bowel CD

          -  Subjects with evidence of other serious infectious, autoimmune, hepatic,nephritic or
             systemic disease or compromised organ function

          -  Subjects with a history of GI tract malignancy or IBD-associated malignant changes in
             the intestines
Clinical trial NCT00411424 (phase 1/phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: ask8007, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  meet the American Rheumatism Association (ARA) 1987 revised criteria for the
             classification of RA (also referred to as the American College of Rheumatology [ACR]
             criteria);

          -  being treated with an adequate dose (to the discretion of the local physicians) of
             either MTX or leflunomide (LEF)or sulfasalazine (SS2) for at least 4 months prior to
             baseline of which the last 6 weeks before baseline were at a stable dose;

          -  have active poly-arthritis (i.e. active rheumatoid arthritis as defined in detail in
             the protocol)

        Exclusion Criteria:

          -  have been treated with any registered or non-registered investigational drug in the
             context of a clinical intervention study during the last 3 months before baseline;

          -  have been treated with TNFα-blockers within a certain period of time (defined for each
             medication) before baseline;

          -  have been treated with any DMARD other than MTX, LEF or SS2 during the last month
             before baseline;

          -  documented evidence for the presence of clinically severe, unstable, or uncontrollable
             renal, hepatic, respiratory, hematological, genitourinary, cardiovascular, endocrine,
             neurological, psychiatric, or other medical illness which would, in the opinion of the
             investigator, put the patient at safety risk or mask measures of efficacy.
Clinical trial NCT00379587 (phase 1/phase 2, status: completed)
Conditions: hematological malignancies
ICD codes: P61.9, P61.8, O28.0, T45.8X6S, T45.96XS, T45.8X3S, T45.8X4S
Drugs: rituximab, 375 mg/m2 rrituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have undergone either ablative or non-myeloablative allogeneic stem cell
             transplantation

          -  Peripheral blood stem cells must have been used as the stem cell source

          -  Patients must have received transplantation from donors who are identical at 6 HLA
             loci, or mismatched at no more than 1 locus.

          -  Patients who have undergone a non-myeloablative stem cell transplant must have > 80%
             donor hematopoiesis within 30 days of study enrollment

          -  18 years of age or older

          -  Performance Status 0-2

          -  Life expectancy of > 100 days

          -  Subjects with CLL are eligible, if there is no more than 20% residual leukemia in the
             bone marrow at the time of study entry

        Exclusion Criteria:

          -  Evidence of relapsed or residual malignancy within 30 days of trial entry

          -  Highly aggressive B cell malignancy, such as Burkitt's lymphoma or Burkitt's-like
             lymphoma

          -  Allogeneic stem cell transplantation using a single or multiple umbilical cord blood
             units or using bone marrow

          -  Evidence of any active uncontrolled infection, or evidence of natural exposure to
             Hepatitis B, Hepatitis C or HIV

          -  Evidence of ongoing gastrointestinal or hepatic acute GVHD, or evidence of greater
             than ongoing Stage I cutaneous acute GVHD

          -  GVHD with chronic features diagnosed prior to day +100 or prior to enrollment

          -  Participation in a clinical trial evaluating another preventative strategy for chronic
             GVHD, or ongoing participation in a clinical trial for therapy of acute GVHD

          -  No Donor Lymphocyte Infusion (DLI) prior to day 100 and not plans for a DLI in the
             upcoming 30 days

          -  Heart failure uncontrolled by medications

          -  Pregnancy or lactation
Clinical trial NCT00298168 (phase 1/phase 2, status: completed)
Conditions: kidney diseases
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: yspsl, placebo, yspsl
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing primary cadaver renal transplants

        Exclusion Criteria:

          -  Patient has a planned transplant of a donor kidney from a non-heart beating donor

          -  Patient has a planned transplant of kidneys that are implanted en bloc (dual kidney
             transplant) or from donors < 6 years of age

          -  Patient has a planned transplant of a kidney from a donor who has received
             investigational therapies designed to reduce the impact of ischemia/reperfusion (I/R)
             injury, DGF, or other donor-related immune events

          -  Patient is planned to receive a living donor kidney; or patient is planned to receive
             an ABO-incompatible donor kidney
Clinical trial NCT01230853 (phase 1, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: active comparator: a, placebo comparator b, active comparator b, placebo comparator a
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion:

          1. Clinical diagnosis of probable mild to moderate Alzheimer's disease (AD) by National
             Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's
             Disease and Related Disorders Association Alzheimer's (NINCDS-ADRDA) criteria.

          2. A Mini Mental State Examination (MMSE) score of 16 to 28, inclusive, at Screening.
             Subjects recruited to the first 2 SAD cohorts should have an MMSE of > 22.

          3. Where symptomatic treatment of Alzheimer's disease (AD) is clinically indicated,
             subjects must be on stable treatment (e.g., with an anticholinesterase inhibitor
             [AChEI] and/or memantine) for at least 12 weeks prior to the Screening visit.

          4. On stable doses of all other prescribed medications for at least 4 weeks prior to the
             screening visit.

        Exclusion:

          1. Any neurological condition that could be contributing to cognitive impairment above
             and beyond that caused by the subject's Alzheimer's disease (AD).

          2. Any psychiatric diagnosis or symptoms, e.g hallucinations, major depression, or
             delusions, that could interfere with assessment of cognition in the subject.

          3. History of transient ischemic attack (TIA), stroke, or seizures within 12 months of
             Screening.

          4. Evidence of infection, tumor, stroke or other clinically significant lesions that
             could indicate a dementia diagnosis other than AD on brain magnetic resonance imaging
             (MRI) at Screening.

          5. Other significant pathological findings on brain MRI at Screening, including but not
             limited to: more than 3 micro-hemorrhages, single macro-hemorrhage; evidence of
             vasogenic edema; evidence of cerebral contusion, encephalomalacia, aneurysms, vascular
             malformations or space occupying lesions.
Clinical trial NCT00255489 (phase 1, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent

          -  Patients requiring low dose palliative thoracic irradiation to a field size of less
             than or equal to 150cm2

          -  Histologically or cytologically conformed non-small cell lung cancer

          -  Aged 18 or over

        Exclusion Criteria:

          -  Previous thoracic radiotherapy

          -  Any condition that may pre-dispose the patient to suffer an individual drug-relaged
             DLT (dose limiting toxicity) event

          -  Known hypersensitivity to any component of study medication